Glipizide 2.5mg Tablets bulk supplier for pharma manufacturers

Glipizide 2.5mg Tablets 2.5 mg, 5 mg, 10 mg Suppliers & Bulk Manufacturers

Available Forms: ER Tablets

Available Strengths: 2.5 mg, 5 mg, 10 mg

Reference Brands: Glucotrol XL(US)

Category: Diabetes

Glipizide ER tablets stimulate insulin release from pancreatic beta cells by blocking ATP-sensitive potassium channels, enhancing postprandial and basal glucose control. The extended-release formulation offers steady drug levels, reduced dosing frequency, and minimized peaks, helping lower the risk of hypoglycemia while effectively managing type 2 diabetes. Ideal for once-daily use.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Glipizide 2.5mg Tablets? List it or send an offer →

Product Description:

Glipizide ER tablets are FDA-approved in the USA for managing type 2 diabetes mellitus, helping patients achieve improved glycemic control. Marketed under brands like Glucotrol XL, the ER formulation allows once-daily dosing with steady plasma levels. In the European Union, availability varies by country, and while not as widespread, glipizide ER is recognized under specific regulatory pathways. EU regulators emphasize cardiovascular safety and monitoring of hypoglycemia risk. Manufacturers must comply with pharmacovigilance, GMP, and labeling standards. For B2B bulk sourcing, compliant and vetted suppliers can be accessed through platforms like Pharmatradz.com, supporting global regulatory demands.

Glipizide 2.5mg Tablets — third party manufacturing & bulk supply

Glipizide 2.5mg Tablets 2.5 mg, 5 mg, 10 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Glipizide 2.5mg Tablets is supplied as ER Tablets — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Glipizide 2.5mg Tablets listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Glipizide 2.5mg Tablets →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Glipizide tablets are used to control high blood sugar levels in patients with type 2 diabetes mellitus. They help reduce the risk of diabetes-related complications such as kidney damage, nerve problems, blindness, and cardiovascular diseases when used along with proper diet and exercise.

Glipizide tablets are made from glipizide, a second-generation sulfonylurea that works by stimulating insulin release from the pancreatic beta cells and improving glucose utilization in the body.

Common trade names include Glucotrol, Glucotrol XL, Minidiab, Melizide, and several generic brands available across the USA, EU, UK, India, and LATAM markets.

More than one company makes it, including manufacturers in India. Share your market and we will find licensed makers whose documents fit.

The complete generic name is glipizide.

Brand names include Glucotrol, Glucotrol XL, Minidiab, Melizide, and various country-specific generic brands.

Glipizide tablets are manufactured globally in countries such as the USA, UK, EU nations, India, and LATAM regions by both innovator and generic pharmaceutical companies.